Suspension of trading
Canntab Therapeutics Limited Stock Deutsche Boerse AG
Stocks
TBF1
CA1377991023
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000500 EUR | -.--% |
|
-.--% | - |
| 15/04/24 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
| 3 years | 0 |  | 0.02 |
| 5 years | 0 | | 0.52 |
| 10 years | 0 | | 1.37 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | - | 15/05/2020 | |
Frank Candido
IRC | Investor Relations Contact | 61 | 01/09/2018 |
Eric Malinski
SAM | Sales & Marketing | - | 01/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 38 | |
| +0.85% | -2.10% | -8.41% | -6.23% | 13.54B | |
| +1.24% | -2.42% | +5.79% | +3.21% | 5.11B | |
| +0.40% | -3.72% | -30.92% | -55.78% | 5.11B | |
| -0.59% | +1.02% | +5.69% | -29.71% | 4.18B | |
| +0.08% | -1.69% | -6.84% | -4.86% | 3.69B | |
| -0.04% | -3.58% | -2.15% | +4.52% | 3.54B | |
| -0.57% | -1.70% | -3.04% | +15.95% | 3.46B | |
| -0.50% | -0.56% | -12.42% | -15.41% | 2.48B | |
| +0.67% | -3.03% | -3.07% | +43.25% | 1.87B | |
| Average | +0.15% | -1.12% | -6.15% | -5.01% | 4.78B | |
| Weighted average by Cap. | +0.36% | -1.12% | -6.94% | -8.87% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- CTABF Stock
- TBF1 Stock
Select your edition
All financial news and data tailored to specific country editions
